Nocturnal Sleep In Mothers May Be Improved By Bright Light Therapy

Bright light therapy may improve a mother's nocturnal sleep, decrease daytime sleepiness and be beneficial to her well-being, according to a research abstract presented on Monday at SLEEP 2008, the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS).



The study, authored by Shih-Yu Lee, PhD, of Georgia State University, focused on 16 first-time mothers with a low birth weight infant hospitalized in the intensive care unit. The subjects were randomly assigned to two groups: the treatment group mothers received a 10,000 lux blue-green bright light therapy for four weeks and the control group mothers received a placebo dim red light therapy. Total sleep time during the day and night was measured by averaging the data obtained from two consecutive days of wrist actigraphy monitoring.



According to the results, the post-treatment average nocturnal total sleep time increased from 383 minutes (6.38 hours) at the baseline to 424 minutes (7.07 hours) for the treatment group mothers. However, the total sleep time in the control group mothers worsened from 413 minutes (6.88 hours) to 373 minutes (6.22 hours). After the four-week intervention, the treatment group mothers' daytime total sleep time decreased from 114 to 39 minutes.



"Having a low birth weight infant in the ICU can intensify sleep disturbances for mothers because of extended periods of exposure to the artificial dim light in the ICU and stress related to the infant's medical condition," said Dr. Lee. "Impaired sleep may have negative impact on the mother's well-being. In our research, we were looking for an intervention to help mothers that would be feasible for them to use even when their infant is hospitalized. The preliminary findings from our pilot study indicate that bright light therapy given through use of the special visor may improve mothers' nocturnal sleep, decrease daytime sleepiness, and be beneficial to their well-being. While our results are promising, a larger scale randomized clinical trial is needed to establish if this would be an effective therapy in this population."



Sleep plays a vital role in promoting a woman's health and well being. Getting the required amount of sleep is likely to enhance a woman's overall quality of life. Yet, women face many potential barriers - such as life events, depression, illness, bad sleep habits and medication use - that can disrupt and disturb her sleep. Overcoming these challenges can help her enjoy the daily benefits of feeling alert and well rested.



It is recommended that women get between seven and eight hours of nightly sleep.



The American Academy of Sleep Medicine (AASM) offers the following tips for women on how to get a good night's sleep:
Follow a consistent bedtime routine.


Establish a relaxing setting at bedtime.















Get a full night's sleep every night.


Avoid foods or drinks that contain caffeine, as well as any medicine that has a stimulant, prior to bedtime.


Do not bring your worries to bed with you.


Do not go to bed hungry, but don't eat a big meal before bedtime either.


Avoid any rigorous exercise within six hours of your bedtime.


Make your bedroom quiet, dark and a little bit cool.


Get up at the same time every morning.

Those who suspect that they might be suffering from a sleep disorder are encouraged to consult with their primary care physician or a sleep specialist.






More information on "women and sleep" is available from the AASM at sleepeducation/Topic.aspx?id=67.



The annual SLEEP meeting (9-12 June, 2008) brings together an international body of 5,000 leading researchers and clinicians in the field of sleep medicine to present and discuss new findings and medical developments related to sleep and sleep disorders.



More than 1,000 research abstracts will be presented at the SLEEP meeting, a joint venture of the AASM and the Sleep Research Society. The three-and-a-half-day scientific meeting will bring to light new findings that enhance the understanding of the processes of sleep and aid the diagnosis and treatment of sleep disorders such as insomnia, narcolepsy and sleep apnea.



SleepEducation, a patient education Web site created by the AASM, provides information about various sleep disorders, the forms of treatment available, recent news on the topic of sleep, sleep studies that have been conducted and a listing of sleep facilities.



Source: Kathleen McCann


American Academy of Sleep Medicine

Antiabortion Advocates Criticize Kansas Sen. Brownback's Support Of Sebelius

Sen. Sam Brownback's (R-Kan.) recent support for HHS Secretary-designate Kansas Gov. Kathleen Sebelius (D) is provoking criticism from antiabortion-rights advocates, who typically have been "enthusiastic backers" of Brownback, the AP/Wichita Eagle reports. Austin Ruse, president of the Catholic Family and Human Rights Institute, said it "makes absolutely no sense" that Brownback, an opponent of abortion rights, would endorse Sebelius, who supports abortion rights. Ruse said the senator "could have remained silent" instead. Troy Newman, president of Operation Rescue, said, "There is profound disappointment within the pro-life community on [Brownback's] position. Politicians stick their fingers up in the air to see which way the wind is blowing, and it's up to the grassroots to make the wind blow."

Brian Hart, a spokesperson for Brownback, said that the senator's office has received "quite a few" phone calls and that there have been angry Internet postings in recent days regarding Brownback's support for Sebelius. Hart said the senator understands the criticism but that he "feels that despite profound policy differences, he should support a fellow Kansan who has been asked to serve by the president." In expressing his support for Sebelius earlier this week, Brownback noted that the "president won the election."

Mary Kay Culp, executive director of Kansans for Life, said Brownback's stance has drawn mixed reactions from the antiabortion-rights movement because some of its members would like to see him replace Sebelius as governor in 2010. Culp said she "disagree[s] with his decision on this, but it doesn't make me question his being pro-life." She added, "We know it doesn't serve the cause of unborn children and their mothers to beat up on" Brownback.

According to the AP/Eagle, criticism of Brownback "seems less vocal in Kansas" because he intends to run for governor, "fulfilling a promise not to run for another Senate term." Sebelius is not allowed to run for a third term under the state Constitution, and she was considered to be the Democrats' best candidate to run for Brownback's vacant Senate seat. If the Senate confirms Sebelius as head of HHS, it "all but ends any chance she'll run," the AP/Eagle reports. Newman said he suspects that Brownback's support for Sebelius is motivated by the GOP's desire to keep his Senate seat in their party. Nonetheless, abortion-rights opponents have been "vocal enough to prompt a counter-campaign" by groups that support Roman Catholic Democrats who support abortion rights, such as Sebelius, the AP/Eagle reports.














Supporters of Sebelius note that the governor has supported efforts to expand adoption and programs to help unmarried pregnant women. In addition, they said the abortion rate has declined in Kansas since she ran for office in 2002. Sebelius, who has also served as state insurance commissioner and a state legislator, said she has "worked pretty diligently for over 20 years to reduce the conditions for women to be in a situation where they feel they have no alternative." She added that she is "proud" that the abortion rate declined by 11% during her time in office. Ruse contended that Sebelius cannot take credit for the Kansas decline, saying that it has occurred all over the country.

Sebelius vetoed antiabortion bills in 2003, 2005, 2006 and 2008. She also has attracted criticism from antiabortion-rights advocates because abortion provider George Tiller attended an April 2007 reception at the governor's residence. Kansas City, Kan., Archbishop Joseph Naumann -- who in 2008 urged Sebelius to stop taking Holy Communion because of her position on abortion rights -- said her nomination is "particularly troubling." Naumann said in a recent blog posting on The Catholic Key that as HHS secretary, Sebelius would be in a position to make decisions "promoting legalized abortion and her cooperation in this intrinsic evil" (Hanna, AP/Wichita Eagle, 3/5).


Reprinted with kind permission from nationalpartnership. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.


© 2009 The Advisory Board Company. All rights reserved.

New Jersey Health Department Releases Records Of Investigation Into Operations Of Abortion Clinic, Reasons Behind Closure

New Jersey Department of Health and Senior Services officials on Tuesday released the records of their investigation of one of the state's largest abortion providers, Metropolitan Medical Associates in Englewood, N.J., after ordering the clinic to close last month, the Bergen Record reports (Padawer, Bergen Record, 3/14). Metropolitan Medical, which opened in the 1970s, performs more than 10,000 abortions annually and is one of the few clinics in the state that performs abortions up to 24 weeks' gestation. Rasheedah Dinkins, who had an abortion at Metropolitan Medical, earlier this month filed a lawsuit in the State Superior Court in Newark, N.J., against the clinic, charging clinic physicians Keith Gresham and Nicholas Kotopoulos with "negligent, careless and reckless care." According to Dinkins' lawyer Adam Slater, Dinkins on Jan. 27 went to Metropolitan Medical to have an abortion of a fetus at more than 15 weeks' gestation. After the procedure, she had pains and was taken to Newark Beth Israel Medical Center, where she was unconscious for more than three weeks, had two strokes and was forced to undergo a hysterectomy, according to Slater. Newark Beth Israel filed a complaint against Metropolitan Medical to the state health department (Kaiser Daily Women's Health Policy Report, 3/2). Investigators in separate records released on Tuesday concluded that Metropolitan Medical failed to notify the health department "of an event occurring within the facility that jeopardized the health and safety of a patient." The department declined to release details of the event, the Record reports (Bergen Record, 3/14).

Investigation Findings, Reaction
The health department after a licensing inspection last month ordered the clinic to stop seeing patients after finding violations that posed "immediate and serious risk of harm to patients" (Kaiser Daily Women's Health Policy Report, 3/2). According to investigation records, state health officials found "brownish blood-like residues" encrusted on forceps, rusty crochet hooks used to remove intrauterine devices, and one-quarter-inch of dark red "dirt and debris" under an examination table at the clinic. Health officials also found that the clinic could not provide evidence that it had an infection-control plan or of an infection-control specialist on staff. The clinic had a letter on file documenting the appointment of a particular employee as the infection-control professional; however, that employee was not familiar with the appointment. The employee also had not received training or certification in infection control and prevention, which is a violation of state law. The report found that packs of sterilized instruments, which are supposed to be opened just before their use, had been unsealed and left open in storage. In other areas of the clinic, investigators found open packages of sterilized speculums, scissors, forceps and clamps, and some surgical instruments were found in the same drawer as light bulbs, the Record reports. According to the records, the clinic failed to train janitorial personnel upon employment and annually about proper cleaning procedures and equipment care, as is required by law. In addition, the health department found that a clinic patient who is suing for malpractice had incomplete medical and operative records (Bergen Record, 3/14). The state is requiring the clinic to hire infection-control and administrative consultants, both of whom must be approved by the state and be at the clinic at least 40 hours per week. The consultants "shall have full authority to review, revise, if necessary, and implement all facility policies and procedures," the order said. In addition, the consultants must submit weekly written reports to the health department (Kaiser Daily Women's Health Policy Report, 3/2). Representatives of the health department and the clinic say the clinic is working to correct the problems and hoping to resume operations as soon as possible. "It is clear that facility is going through an extremely rigorous review," Frank Capece, attorney for Metropolitan Medical, said. He added, "We can debate whether that is arbitrary or necessary, but it's a moot point. It is the intention of the facility to be in full compliance with all requirements. And it's my perception that everyone's working in good faith. ... There's no doubt that we're being held to a strict standard, a tougher standard than any other facility that we know of" (Bergen Record, 3/14).














"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

FDA Advisory Committee To Review Genentech's Avastin For Use As Breast Cancer Treatment

Genentech on Thursday announced that an FDA advisory panel in December will review its colon and lung cancer treatment Avastin as a first-line treatment for metastatic breast cancer, Reuters reports (Baertlein, Reuters, 9/13).

Genentech in May 2006 filed for FDA priority review of its application to use Avastin as a breast cancer treatment based on data from a late-stage clinical trial. The trial -- which involved 722 patients with previously untreated, locally recurrent or metastatic breast cancer -- found that Avastin reduced the risk of disease progression or death by 52% for patients who used the treatment with chemotherapy, compared with patients who only underwent chemotherapy.

Avastin -- which costs about $50,000 annually as a treatment for colon cancer -- might cost as much as $100,000 to treat breast cancer because breast cancer patients would require a double dose of the drug. FDA in September 2006 requested that Genentech provide more thorough data than it gave in the late-stage trial -- which was organized by National Cancer Institute researchers -- as well as require radiologists not involved in the trial to determine when patients' cancer has worsened (Kaiser Daily Women's Health Policy Report, 9/12/06).

According to Reuters, FDA's Oncologic Drugs Advisory Committee in December will consider the application. FDA is expected to take action on the application by Feb. 23, 2008 (Reuters, 9/13). Avastin, which is approved as a breast cancer treatment in the European Union, increasingly is being prescribed off-label to treat breast cancer, Dow Jones reports (Gryta, Dow Jones, 9/13).

Reprinted with kind permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


View drug information on Avastin.